Somite Raises $5.3M in Pre-Seed Funding to Advance AI-Driven Stem Cell Biology for Regenerative Medicine
Somite aims to revolutionize stem cell biology with its digital twin of the embryo and sophisticated AI-driven models, facilitating rapid development and optimization of cell therapies.
Company Name: Somite
Location: Boston, MA
Sector: Biotechnology
Funding Details: Raised $5.3M in Pre-Seed funding, led by TechAviv. Other participants include Next Coast Ventures, Trust Ventures, Texas Venture Partners, Lerer Hippeau, and others.
Purpose of Investment: To continue the development of its proprietary AlphaStem AI platform.
Leadership: CEO Micha Breakstone, alongside key team members Jonathan Rosenfeld (CTO), Carl Morris (Chief Scientific Officer), Kristy Brown (SVP Translational Development), and scientific co-founders Olivier Pourquie, Allon Klein, and Cliff Tabin.
Product: Somite is developing AI foundation models to produce human tissue for cell therapies at scale, addressing diseases such as diabetes, obesity, and muscular dystrophies. Its AlphaStem platform leverages AI to enhance the production and application of cell therapies.
About Company: Somite aims to revolutionize stem cell biology with its digital twin of the embryo and sophisticated AI-driven models, facilitating rapid development and optimization of cell therapies.
